New Science Ventures

New Science Ventures (NSV) is a premier venture capital firm established in 2004, with offices in New York and London. The firm specializes in investing in companies that leverage groundbreaking scientific innovations in the life sciences and information technology sectors. NSV has a keen focus on businesses with strong IP protection and those addressing significant unmet market needs. Notable investments include Ventyx Biosciences, Phase Four, Achronix Semiconductor, and Paragraf. NSV is particularly interested in companies that can transform their industries with innovative scientific approaches. Their strategy is to invest in both early and mid-stage companies, supporting them through crucial growth phases to maximize their potential and value. NSV is not afraid to take contrarian views and often seeks opportunities outside traditional tech hubs, emphasizing the importance of science-based innovation. The firm typically leads funding rounds and provides substantial follow-on support, ensuring that their portfolio companies have the resources needed to succeed. Key team members include co-founder Tom Lavin, who brings over 30 years of experience in finance and investment banking, and Raju Mohan, a seasoned biotech entrepreneur and senior advisor with extensive expertise in drug discovery and development. Startups looking to engage with NSV should emphasize their scientific uniqueness and potential for significant market impact. NSV values strong management teams and clear, defensible IP strategies, making these essential points of focus when approaching the firm.